Back to search results

DCE-MRI Guided Chemotherapy for Borderline Resectable Pancreatic Cancer

This study is testing if chemotherapy guided by a special imaging method called Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) can better shrink pancreatic tumors that are "borderline resectable." This means the tumor is currently difficult to remove with surgery but might become removable after treatment. Researchers at UAB have been studying DCE-MRI for over 10 years; it measures blood flow in tissues, which can indicate a tumor's status. The goal is to see if using DCE-MRI to guide chemotherapy can make surgery possible for more patients. You may be able to join if you are an adult (19 or older) with newly diagnosed, untreated borderline resectable pancreatic cancer. The study is enrolling 50 participants, but its current recruitment status is unclear. Success for this study means showing that DCE-MRI measurements of these tumors are reliable and consistent.

Study design
This interventional study plans to enroll 50 adult participants with borderline resectable pancreatic cancer.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at 6 weeks (+/- 2 weeks).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06173310

DCE-MRI Guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer

Recruiting
NAAges 19+InterventionalDiagnostic
Ohio State University
~50 participants
Updated 2026-02-27 on ClinicalTrials.gov
What's tested:Point-of-care Portable Perfusion Phantom (P4)

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To measure the reproducibility of qDCE-MRI measurement of BRPC.
Measured over 6 weeks +/- 2 weeks

Conditions

Borderline-resectable Pancreatic Cancer

Explore related trials

Pancreatic Carcinoma

Where it's being run

2 sites across 2 states
Indiana1
Ohio1

Study leadership

  • Harrison Kim, PhD · PRINCIPAL_INVESTIGATOR · Ohio State University

Who to contact

Tamara Stein, MPH
[email protected]
614-293-8315
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adult patients (age 19 years or older).
Patients with newly diagnosed and untreated borderline resectable pancreatic cancer.
Patients with signed informed consent.

Exclusion

Any history of prior radiation or chemotherapy or surgical removal for pancreatic cancer.
Participants with safety contraindications to MRI examination (determined by standard clinical screening).
Participants who are pregnant, lactating or are planning to become pregnant during the study.
Participants who are planning to father a child during the study.

What this trial measures

  • To measure the reproducibility of qDCE-MRI measurement of BRPC.6 weeks +/- 2 weeks

    The pharmacokinetic (PK) parameter within the region of interest (ROI) will be averaged at each scan after P4-based error correction, and the mean values of two scans will be compared to calculate the reproducibility coefficient (%RDC) using the equation, %RDC=2.77wCV, where wCV is the within-subject coefficient of variation. The %RDC before P4-based error correction will also be calculated for comparison. Data reproducibility will be assessed using the intra-class correlation coefficient (ICC) as well. ICC = σ 2b / (σ 2b+ σ 2w), where σb is between-subject standard deviation and σw is within-subject standard deviation.